App-Quantinova.ai

HDACi Promotes the Occurrence of Ferroptosis in CTCL

Wenyu Shi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non-Hodgkin's Lymphoma

N/A

PP2A Inhibitor LB100 Enhances the Sensitivity of NPM-ALK+ALCL to Crizotinib and Reverses the Resistance of ALCL to Crizotinib

Wenyu Shi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Cyclophosphamide

Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway

Yuanfang Tang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non-Hodgkin's Lymphoma

chiauranib

Clinical Characteristics and Stratified Analysis of Ph-like Acute Lymphoblastic Leukemia in Children: A Retrospective Study from China

Xiaoyan Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

NUP98-HOXA9 Bearing Acute Myeloid Leukemia

Yi Fang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Gastrointestinal bleeding

Vidaza

Clinical Feature and Effect of Demethylation Therapy in Pediatric Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Yang Wan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

N/A

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Tapan M. Kadia - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic myelomonocytic leukemia

Vidaza

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center

YinJun Lou - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Glucocorticoid

Maintenance Therapy with Combination of Azacitidine, Danazol and Thalidomide after Intensive Chemotherapy in Acute Myeloid Leukemia Patients

Fang Zheng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Daunorubicin

Novel Therapeutic Combining CS055 with Chiglitazar Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

Hui Zhou - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

chiglitazar

Screening of Differential DNA Methylation Sites and Signal Pathway Analysis of Juvenile Myelomonocytic Leukemia in Children before and after Decitabine Treatment

Junbin Huang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leukemia, juvenile myelomonocytic

Decitabine

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Guopan Yu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Venetoclax

Heme Oxygenase-1 Inhibition the Cytotoxicity of NK Cells to AML By Downregulating HLA-C

Cheng Feng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heme oxygenase 1 deficiency

Cytarabine liposomal

Therapeutic Effect of Bortezomib Combined with Dag Regimen in Hyperleukocytic Acute Myeloid Leukemia

Xinqi Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Doxorubicin

Chidamide Combined with Cytarabine Plays a Role in the Treatment of AML By Down-Regulating the MYC-RRP9 Pathway

Qing LI - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cytarabine liposomal

Circ_0100160 Derived from FLT3 Is a Novel Diagnostic Biomarker in Acute Myeloid Leukemia

Yuxing Liang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Omacetaxine mepesuccinate

Identification of TSC22D3 As a Novel Immune-Related Prognostic Biomarker of Acute Myeloid Leukemia

Yang Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Glucocorticoid

Single Institution Observational Study of Risk-Adapted Therapy for Children with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Yixin Hu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Filters

24782 Abstracts